eNauka - pregled
Pregled prema Projekat Merck KGaA, Darmstadt, Germany
Prikaz rezultata 1 do 5 od 5
Godina | Naslov | Autor(i) | Tip rezultata | Mp-kat. |
---|---|---|---|---|
2014 | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial | Stupp, Roger; ...; Grujicic, Danica M; ...; (broj, koautora 37) | Naučni članak | 21aM21a - Rad u međ. časopisu izuzetnih vrednosti |
2012 | Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: Further outcomes from the IMPROVE study | De, Stefano Nicola; Sormani, Maria Pia; Stubinski, Bettina; Blevins, Gregg; Drulovic, Jelena S ![]() ![]() | Naučni članak | 22M22 - Rad u istaknutom međ. časopisu |
2021 | First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC) | Andric, Zoran G; ...; Stojanovic, Goran; Petrovic, Marina D ![]() ![]() | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
2018 | Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer | Van, Cutsem Eric; Hidalgo, Manuel; Canon, Jean-Luc; Macarulla, Teresa; Bazin, Igor; Poddubskaya, Elena; Manojlovic, Nebojsa S; Radenkovic, Dejan V; Verslype, Chris; Eric, Raymond;
Cubillo, Antonio; Schueler, Armin; Zhao, Charles; Hammel, Pascal;
| Naučni članak | 21M21 - Rad u vrhunskom međ. časopisu |
2015 | Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study | Nabors, Louis Burt; ...; Grujicic, Danica M; ...; (broj, koautora 17) | Naučni članak | 21aM21a - Rad u međ. časopisu izuzetnih vrednosti |